Pacific Biosciences is trading at $1.78, up 10.19%, with no clear company-specific catalyst identified for the September 28, 2026 rise.
- Recent coverage of cost savings and sequencing strategy predates the session.
- Major indices are down, so broader-market weakness does not explain the stock’s gain in the same direction.
- Recent sessions were volatile, but available reporting does not establish a direct cause for the move.